Craig Shimasaki discusses Moleculera Biosciences' diagnostic approach for neuroinflammation and commercialization challenges
Summary
Host Elaine Hamm interviews Craig Shimasaki, CEO of Moleculera Biosciences, about the company's focus on neuroinflammation and immune dysfunction in chronic neuropsychiatric disorders. Shimasaki explains the company's diagnostic approach for conditions like PANDAS and highlights the significant patient journey involving multiple doctors and high costs before diagnosis. He notes that Moleculera has tested nearly 19,000 patients through a CLIA-certified lab without traditional sales forces, relying instead on patient advocacy. The discussion covers the complexities of commercializing diagnostics in a fragmented healthcare system and the need for clinical science liaisons to educate physicians. Shimasaki also shares entrepreneurial lessons on managing uncertainty and the importance of segmenting markets by behavior to find early adopters.
Episode sections
- 0:00 – 2:15
Introduction and Company Overview
Host Elaine Hamm introduces guest Craig Shimasaki, CEO of Moleculera Biosciences. Shimasaki explains that the company focuses on neuroinflammation and immune dysfunction related to chronic neuropsychiatric disorders like ADHD, bipolar disorder, and pre-symptomatic Alzheimer's.
- 2:15 – 3:51
PANDAS/PANS and Diagnostic Approach
Shimasaki discusses PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections), explaining how strep antibodies can cross-react with brain tissue. He states the goal is to identify immune-mediated events so patients can be treated and recover.
- 3:51 – 6:45
Clinical Testing Volume and Patient Journey
Shimasaki reports that the company has clinically tested nearly 19,000 patients through a CLIA-certified lab across over 50 countries without salespeople. He notes that patients often see 5-15 doctors and spend $20-$100k over 3-7 years before finding the correct diagnosis.
- 6:45 – 9:56
Commercialization Challenges and Sales Strategy
The speakers discuss the complexity of selling to a fragmented medical system. Shimasaki explains they are raising capital to hire clinical science liaisons to educate doctors, as the current model relies on patients finding them via social media and word-of-mouth.
- 9:56 – 13:25
Entrepreneurial Lessons and Managing Uncertainty
Shimasaki advises scientists to embrace uncertainty, acting as a 'chief uncertainty officer.' He emphasizes that biological failures require more capital or time, and business success depends on understanding the distinct value propositions for patients, doctors, and payers.
- 13:25 – 17:10
Market Segmentation and Adoption
Referencing Geoffrey Moore's 'Bridging the Chasm,' Shimasaki stresses the importance of segmenting by behavior rather than demographics to find early adopters. He notes the company now has 3,200-3,200 prescribing clinicians, with 10-15 new sign-ups weekly.
Claims worth verifying
Moleculera Biosciences focuses on neuroinflammation and immune dysfunction related to neuropsychiatric disorders like ADHD, bipolar, and pre-symptomatic Alzheimer's.
Unidentified speaker (speaker_2) ·1:30
How to verify: Company website (moleculera.com) or press releases describing their diagnostic focus. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
PANDAS stands for Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections.
Unidentified speaker (UNKNOWN) ·2:15
How to verify: Medical literature or CDC/NIH definitions of PANDAS/PANS. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
The company has clinically tested almost 19,000 patients through a CLIA-certified lab.
Unidentified speaker (speaker_2) ·3:51
How to verify: Company website, annual reports, or direct inquiry to Moleculera Biosciences. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Patients saw an average of 5-15 doctors over 3-7 years and spent $20,000-$100,000 before finding the company.
Unidentified speaker (UNKNOWN) ·5:07
How to verify: Internal company study referenced by Shimasaki; verify via company white papers or direct request. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Moleculera has no salespeople.
Unidentified speaker (speaker_2) ·3:51
How to verify: Company website 'About' section or job postings indicating absence of sales roles. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Moleculera is raising additional capital for clinical science liaisons.
Unidentified speaker (speaker_0) ·6:45
How to verify: SEC Form D filing or company press releases regarding fundraising activities. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Primary sourceThe company has 3,200-3,200 prescribing clinicians, with 10-15 new sign-ups weekly.
Unidentified speaker (speaker_0) ·14:54
How to verify: Company website or direct inquiry to Moleculera Biosciences. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Geoffrey Moore wrote 'Bridging the Chasm' about high-tech adoption.
Unidentified speaker (speaker_2) ·13:31
How to verify: Book publication details (ISBN, publisher) available in any bookstore or library database. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Moleculera's tests are sent to patients in over 50 countries.
Unidentified speaker (speaker_0) ·4:06
How to verify: Company website or patient testimonials on social media/platforms mentioned. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Strep antibodies can cross-react with brain tissue, causing Sydenham chorea and rheumatic fever.
Unidentified speaker (speaker_2) ·2:41
How to verify: Medical textbooks or peer-reviewed journals on rheumatic fever and PANDAS pathophysiology. For recent events, verify 2026-08-18 through 2026-11-18. Use another period only when the speaker explicitly names it.
Do your own research
- Verify Moleculera Biosciences' latest SEC filings (10-K, 10-Q) for financial health, cash burn rate, and recent capital raises.
- Check CLIA certification status and laboratory accreditation details for Moleculera's testing facilities.
- Review peer-reviewed literature on PANDAS/PANS pathophysiology and the validity of strep antibody cross-reactivity with brain tissue.
- Analyze the competitive landscape for neuroinflammation diagnostics, including competitors like Cyrex Laboratory or other functional medicine labs.
- Examine the reimbursement landscape for the specific biomarkers tested by Moleculera to assess payer acceptance.
- Look for independent clinical studies validating the correlation between Moleculera's test results and patient outcomes.
- Assess the regulatory environment for in-vitro diagnostics (IVD) and potential FDA scrutiny on the company's marketing claims.
- Investigate the background and potential conflicts of interest of the clinical science liaisons and key opinion leaders referenced.
Full transcriptexpand
0:00Unidentified speaker (speaker_0): Great Science may launch a company, but what does it take to keep it going?
0:06Unidentified speaker (UNKNOWN): You're
0:06Unidentified speaker (speaker_0): listening to Bio from the Bayou, empowering biotech leaders with the tools, assets, and expertise to improve healthcare outcomes.
0:12Unidentified speaker (speaker_1): Each episode provides insights and information to expand your network, advance your product line, and help your company thrive.
0:18Unidentified speaker (speaker_0): Serving the entire Gulf South, but recorded in the heart of New Orleans.
0:24Unidentified speaker (UNKNOWN): Welcome
0:25Unidentified speaker (speaker_0): back to Bio from the Bayou. I'm your host. Dr. Elaine Ham, the executive in residence at Tulane School of Medicine, and we are recording from New Orleans Bio Innovation Center today in partnership with our Biochallenge event, which is a global pitch competition showcasing the cutting-edge technologies and innovation solutions focused mainly in the neurospace. And today I have an old friend with me, someone I've known for many, many years. I actually was on the board. of your company as an observer many, many years ago. That was my first board experience. And with me today, I have Dr. Craig Shimasaki, who is the CEO and founder of Moleculara.
1:01Unidentified speaker (speaker_2): It's great to see you, Elaine. We have to come to New Orleans to see
1:04Unidentified speaker (UNKNOWN): each other from
1:05Unidentified speaker (speaker_2): Oklahoma.
1:05Unidentified speaker (speaker_0): That's how it goes.
1:06Unidentified speaker (speaker_2): Hey, it's great to see what you're doing and all that's going on here.
1:09Unidentified speaker (speaker_0): Yeah. Well, and I've I've known you for many years. And like I said, it was a vr very it was one of my first board experiences. And what was really eye-opening to me and we first met, and I was sitting there in those board meetings of understanding the amount of time you took to really understand your customers. But before I get into that, what is Molecular? And what are you hoping to solve and do?
1:30Unidentified speaker (speaker_2): Well, that's a long, wide open question,
1:32Unidentified speaker (UNKNOWN): but
1:32Unidentified speaker (speaker_2): it is something that's very important. And actually, I think one of your mentors or professors, Dr. Madeline Kyle. Cunningham,
1:39Unidentified speaker (UNKNOWN): who's my
1:40Unidentified speaker (speaker_2): co-founder. And so 20 years of research from there, what we do is we actually focus on neuroinflammation and immune dysfunction and how it's related to chronic disorders, specifically neuropsychiatric disorders like ADHD, bipolar chronic, other kinds of chronic neurologic disorders. And then we're focusing also on immune. immune-mediated cardiovascular and then identifying pre-symptomatic Alzheimer's that's due to inflammatory-mediated events.
2:11Unidentified speaker (speaker_0): Sure. So just a couple of things.
2:13Unidentified speaker (UNKNOWN): Just a few things.
2:14Unidentified speaker (speaker_2): They are all connected.
2:15Unidentified speaker (UNKNOWN): They're all connected though. And it's related to
2:18Unidentified speaker (speaker_0): not the fuzzy animal, but pandas, which is really interesting.
2:21Unidentified speaker (speaker_2): Yeah. So I'm glad you brought that up. So pandas Panda stands for pediatric autoimmune neuropathics. Neuropsychiatric Disorder Associated with a Strep Infection. And so this is what my co-founder, Dr. Cunningham, had studied strep for a long time. And what they had found out was that when you get strep infections in a genetically susceptible individual, the antibodies they make actually cross-react with a part of that organism that looks like a part of your brain. And therefore you get what's called Sydenham Korea. Part of it also looks like the heart. Then you get rheumatic fever. But it's a medical model that actually helps us understand portions of things like schizophrenia, bipolar, chronic depression, even autism, because the symptoms manifest the same way, but there's that's a different origin.
3:10Unidentified speaker (UNKNOWN): So
3:10Unidentified speaker (speaker_2): our goal is to understand and find those patients that are due to this. immune-mediated vent, have the immune system treated and the inflammation treated, and then they get well.
3:20Unidentified speaker (speaker_0): Yeah. And that seems like such a logical value proposition. And you've had some incredible cases where children, patients, your patients will struggle with certain conditions, whether it's Tourette's or something along those lines. You mentioned autism of really terrible symptoms. And they get this test and then realize that it might be really. related to something like this, an a possible infection event. And then they can drill down on, well, we can treat that. We can do several different types of treatments depending on what the cause of the infection was, and the patients get better.
3:51Unidentified speaker (speaker_2): Absolutely. And it's really that group of people that have been suffering for a long period of time. We've actually clinically tested through our Clea Cola accredited lab almost 19,000. patients. Half of them are adults, but we have no salespeople.
4:06Unidentified speaker (speaker_0): Yeah.
4:07Unidentified speaker (speaker_2): So they have found us, and it's been in over 50 countries. But the stories are remarkable. And that's really the the value of this business is that patients will tell us, in fact, one flew from California to tell us he's still alive today because of our
4:23Unidentified speaker (UNKNOWN): test.
4:24Unidentified speaker (speaker_0): Yeah.
4:24Unidentified speaker (speaker_2): And he wanted to thank every single employer. employee for helping and being a part of it.
4:29Unidentified speaker (speaker_0): Yeah. Well, that kind of keeps you going for sure. But it makes it challenging too. I mean, you mentioned you don't have Salesforce, but this is what I wanted to talk a little bit about. Like what I, as a board observer, just understanding like, how do you find I mean it's a clear value proposition, but it's complicated because what type of doctor are you trying to promote this to? Is it is it a pediatric doctor? Is it neurology? Is it optical? autoimmune disease doctors? It's complicated.
4:53Unidentified speaker (speaker_2): It is, and that's part of the reason they get bounced around in the system.
4:56Unidentified speaker (speaker_0): Absolutely.
4:57Unidentified speaker (speaker_2): And one of the studies we did of over a thousand patients who we had tested, we asked, How many doctors did you see? How much did you spend? Yeah.
5:06Unidentified speaker (UNKNOWN): How
5:06Unidentified speaker (speaker_2): long did it take?
5:07Unidentified speaker (UNKNOWN): Yeah.
5:08Unidentified speaker (speaker_2): On average, it was between five and fifteen doctors before they found out us.
5:12Unidentified speaker (UNKNOWN): Wow.
5:12Unidentified speaker (speaker_2): Between three to seven years, but we've seen ten fifteen. And then they've set up to a hundred thousand dollars. And so for the doctors, it tends to be these specialists that they go to. So maybe they'll present in the ER, then they'll go to a neurologist, then they'll be sent to a psychiatrist, then they'll
5:29Unidentified speaker (UNKNOWN): go to
5:29Unidentified speaker (speaker_2): a social worker. And then round and round and round until finally someone connects the dots
5:35Unidentified speaker (UNKNOWN): and
5:35Unidentified speaker (speaker_2): they figure it out.
5:36Unidentified speaker (speaker_0): Sure.
5:37Unidentified speaker (speaker_2): But I think it's the the challenge for medicine because chronic diseases don't get fixed in like a 20 minute visit
5:44Unidentified speaker (UNKNOWN): or
5:45Unidentified speaker (speaker_2): a very short history in physical. And this is where we need integrative and functional and cross-functional teams to look at these patients.
5:54Unidentified speaker (UNKNOWN): Well,
5:54Unidentified speaker (speaker_0): and I think it shows, I mean, you mentioned that people find you. We don't really have Salesforce necessarily because people find you. And I think that's also the power of patients kind of taking things into their own hands and being their own advocate. And as being on the company side, you have to look at the Reddit forms. You have to look at patient forms, TikToks. I mean, there's tons of TikToks about Potts disease and endometriosis patient journeys. And I think as a drug developer and beyond the company side, you have to take that into account. You can't just dismiss it because it's not in New England Journal of Medicine.
6:25Unidentified speaker (speaker_2): Exactly. And those are the kinds of things in medicine that don't really get as much focus unless there's a patient advocacy group. So
6:32Unidentified speaker (UNKNOWN): you'd
6:32Unidentified speaker (speaker_2): mentioned. And a lot of those social media channels are things where they will go and express themselves. Now, the reason we don't have salespeople is not because we don't need them. It's because this is also in an entrepreneurial business.
6:45Unidentified speaker (speaker_0): So
6:45Unidentified speaker (speaker_2): in an entrepreneurial business, as you well know, you really have to grow it while you're building it. And
6:51Unidentified speaker (UNKNOWN): you
6:51Unidentified speaker (speaker_2): have to demonstrate that there's value and show that there's
6:54Unidentified speaker (speaker_0): success. Yeah.
6:55Unidentified speaker (speaker_2): Success.
6:55Unidentified speaker (speaker_0): Yeah.
6:56Unidentified speaker (speaker_2): So we are raising additional capital and it will be geared towards educating doctors and being able to have what we'll call clinical science liaisons. Yeah. Who will actually teach and train people.
7:07Unidentified speaker (speaker_0): That's a big piece of it. Because I mean, I'm sure doctors have fatigue of patients coming in and saying, Hey, I I found this on the internet. And you're they go, Oh God, what did you find on the internet? But there's a lot of legitimacy in the places. But like as you said, I mean, because you're not talking about a disease, you're talking about more than one, and they're usually very complicated diseases. And so being able to communicate that concisely and bring in the scientific validity that comes with it, I mean, that that's hard for a patient.
7:37Unidentified speaker (speaker_2): It is. We've been amazed though how. that they will spend a lot of time, mostly the moms, they'll spend lots of time looking for data and information. Yeah. But it is something that we have to communicate very well because it's not just the immune system and then the symptoms, but you throw in it's actually an infection that triggers it.
7:56Unidentified speaker (speaker_0): Yep.
7:57Unidentified speaker (speaker_2): And so these infectious triggers, which are common in certain individuals, they'll trigger the immune system to
8:03Unidentified speaker (UNKNOWN): go
8:03Unidentified speaker (speaker_2): awry. So when you throw even that in and you have this clinical picture of infectious disease, rheumatology, immunology, psychiatry, neurology.
8:13Unidentified speaker (speaker_0): Yeah.
8:14Unidentified speaker (speaker_2): Yeah. Okay. How do you unravel all of that?
8:16Unidentified speaker (speaker_0): It's complicated.
8:17Unidentified speaker (speaker_2): But patients get so remarkably well when they get the right testing and they get the answer. And this is why we believe it's going to actually become mainstream. in the future. Yeah,
8:28Unidentified speaker (speaker_0): sure.
8:28Unidentified speaker (speaker_2): Which people will find, oh, that makes all kinds of sense. But in the interim, you have to really do a lot to demonstrate that.
8:35Unidentified speaker (speaker_0): Even though it comes up, I mean, again, the value proposition, the data that's around it, and how remarkably simple in a lot of ways of no, it's an infection, causes inflammation. If we treat the infection and the inflammation, you're going gonna to get better.
8:48Unidentified speaker (speaker_2): Absolutely. And what we're finding also is that the immune system is so important to all of our d uh
8:54Unidentified speaker (UNKNOWN): Oh my gosh.
8:55Unidentified speaker (speaker_0): Yeah. Yeah. Yeah.
8:56Unidentified speaker (speaker_2): Including cancer.
8:57Unidentified speaker (UNKNOWN): Um
8:58Unidentified speaker (speaker_2): including we're doing cardiovascular disease assessing now.
9:01Unidentified speaker (speaker_0): And you mentioned dementia too. That I mean
9:03Unidentified speaker (UNKNOWN): it's
9:03Unidentified speaker (speaker_0): all I mean I think we'll find later it's all going to come down to the immune system for sure.
9:08Unidentified speaker (speaker_2): Absolutely, because even though we take antibiotics for infections, sure it's our immune system that eventually clears it out at the end of the day.
9:15Unidentified speaker (UNKNOWN): But it
9:15Unidentified speaker (speaker_2): just gives the the body a fighting chance. And so, yes, the better we have an immune health and strong immune system, the better. And probably it'll involve in longevity also. Yeah.
9:27Unidentified speaker (speaker_0): Yeah, absolutely. Which is the new sexy thing. So it's how do we live longer? So but I want to learn how to live better, not just longer.
9:35Unidentified speaker (UNKNOWN): So
9:36Unidentified speaker (speaker_0): well, so I mean we've known each other for a while and you've been on this journey for quite some time too. And at a time where the importance of the immune system and well, hell, maybe even Reddit wasn't a thing. What have you what are the biggest I mean you teach entrepreneurship too. What are the biggest takeaways? And we have a lot of our audience members are scientists and they're entrepreneurs. What are some big takeaways that you would recommend?
10:00Unidentified speaker (speaker_2): Yeah, first of all, every scientist that starts a company or physician or engineer is going to be a first time CEO. And I like to tell them that because of your background training, you have the capability to be an excellent business person. If you focus on it, and if you enjoy it. Oh,
10:17Unidentified speaker (speaker_0): there's a rub.
10:18Unidentified speaker (speaker_2): There you go.
10:18Unidentified speaker (UNKNOWN): Oh, two. That's
10:19Unidentified speaker (speaker_0): two things. Focus and I have to enjoy it. Oh
10:22Unidentified speaker (speaker_3): no.
10:22Unidentified speaker (speaker_2): Well, because we're trained in the scientific method. You
10:25Unidentified speaker (UNKNOWN): want to
10:25Unidentified speaker (speaker_2): find and you test and prove high. hypotheses,
10:27Unidentified speaker (UNKNOWN): you
10:28Unidentified speaker (speaker_2): do things to be sure that there's data to support it. Yep. Before you make decisions and then you decide on a pathway to go. And then you collect data along the way and be sure that's what you're doing. And if you do that in the business side of it, you can make better business decisions. The challenge for these, and especially for entrepreneurs, errors is when we combine biology and business, we create a business of uncertainty.
10:51Unidentified speaker (speaker_0): Sure.
10:51Unidentified speaker (speaker_2): And so what you're trying to do is you have to be the manager of uncertainty or the chief uncertainty officer where you're having when something goes wrong or doesn't go away it should be in the biology, that means you have to raise more money. And it takes longer to do something.
11:07Unidentified speaker (speaker_0): Yeah.
11:07Unidentified speaker (speaker_2): Or if that doesn't work in that way, you may not have a specific feature or benefit that you were intending to for your market or for your audience. Sure. But you still have to figure all of that out while you're doing it. And so the better you are at doing that, the more opportunities for success you can have.
11:25Unidentified speaker (UNKNOWN): Well,
11:25Unidentified speaker (speaker_0): it's got to be really frustrating and hard though. When you have the scientific data, you have patients tell coming and flying to your lab and shaking your hand. That's got to be really hard when the traction on the business side, whether it's funding or sales. or doctors that you're still having to explain the same thing over and over and they don't get it, I mean, that's got to be really hard because there's two sets of data. You have the scientific data, but the business data is hard.
11:49Unidentified speaker (speaker_2): It is because you need the business side and you need the scientific one. And what we have found is that if you approach really how you grow a business in the same way, because let's say not every specialty is an early adopter. You know, they might be a specialty that sees these patients, but they may not be the partition of that group that's
12:09Unidentified speaker (UNKNOWN): an
12:09Unidentified speaker (speaker_2): early adopter. So you have to partition that group too, because otherwise what you find is you spend a lot of time doing something over and over and they've already made up their mind. They've
12:21Unidentified speaker (speaker_0): already made up yeah. And physicians are you have a hard customer. I mean, well, you have lots of different customers in your ecosystem because you have moms, the patients, all of these things, but also doctors and doctors are notoriously hard to sell to.
12:33Unidentified speaker (speaker_2): And it's tough business because they're in a system where they don't get to see or
12:38Unidentified speaker (UNKNOWN): get
12:38Unidentified speaker (speaker_2): rewarded or compensated for spending, let's say, an hour with a patient who've
12:43Unidentified speaker (UNKNOWN): got
12:43Unidentified speaker (speaker_2): a chronic disease. So we have to do something in the medical system. And what I
12:49Unidentified speaker (UNKNOWN): try
12:49Unidentified speaker (speaker_2): to remind other entrepreneurs. is the area you and I work in is the most unique industry because the person who actually orders something doesn't use it.
12:59Unidentified speaker (speaker_0): Yeah.
12:59Unidentified speaker (speaker_2): The person who uses it doesn't pay for it. Person who pays for it doesn't order it or use. Yeah. And they all want something of value. Yeah.
13:07Unidentified speaker (UNKNOWN): And
13:07Unidentified speaker (speaker_2): if you don't give it to them, then And it doesn't actually take hold and and move forward. So if you can figure out the value of propositions for each of those, you generally will have less resistance.
13:19Unidentified speaker (UNKNOWN): Yeah.
13:20Unidentified speaker (speaker_2): I'm not gonna say it's easier because it's never easier. It's just less difficult.
13:25Unidentified speaker (speaker_0): Looking back on your journey though, is there anything that you wish you hadn't done or maybe spent more or less time on?
13:31Unidentified speaker (speaker_2): Yeah. And I think it was uh I'll call it segmenting. There's a book called Uh Bridging the Chasm. I
13:37Unidentified speaker (UNKNOWN): don't know if
13:37Unidentified speaker (speaker_2): you've read that. Uh Jeffrey Moore's book on high tech adoption of really anything and how it uh there's innovators and there's early adopters, then there's a big gap between the early majority. And unless you actually transition over to the early majority, which are the people that aren't just gonna stand in line for the latest iPhone and
13:57Unidentified speaker (UNKNOWN): all
13:58Unidentified speaker (speaker_2): of that. They're the ones who prove it to me. Yeah. Show me more data and then let me see it actually work. And then once you cross that over, then you actually get into the mainstream audience. So I wish I would have probably understood there's a segmentation, not by demographics.
14:16Unidentified speaker (UNKNOWN): Yeah.
14:17Unidentified speaker (speaker_2): It's actually behavior.
14:18Unidentified speaker (speaker_0): Yeah. And
14:19Unidentified speaker (speaker_2): if you segment by behavior, you actually have a better opportunity to find the right audience. Yeah.
14:25Unidentified speaker (speaker_0): And
14:26Unidentified speaker (speaker_2): then once they actually adopt, then you can actually show the data and show people getting well. Yeah. And then it does catch on. And
14:32Unidentified speaker (speaker_0): then they then they're the evangelists for your product. It's not just the one and done, they're all try it. It's yeah, I I didn't really like it, but whatever. And you gotta find the people who are like, nope, it took me a while to get there, but once I was there, I mean, they are the people that are doing your sales
14:46Unidentified speaker (UNKNOWN): for you.
14:46Unidentified speaker (speaker_2): So we have thirty 3,200 two hundred prescribing clinicians now. We get 10 to 15 new ones find out about us and sign up.
14:54Unidentified speaker (speaker_0): Yeah.
14:55Unidentified speaker (speaker_2): And over 50 countries they've been sending to us. And we do know because they are doing it and using it because they see results in their patients. And the the whole goal of all of this is to how do we better help them get their patient well quicker?
15:13Unidentified speaker (speaker_0): Yeah.
15:13Unidentified speaker (UNKNOWN): Yeah.
15:13Unidentified speaker (speaker_2): Yeah.
15:14Unidentified speaker (speaker_0): Make people feel better.
15:15Unidentified speaker (speaker_2): Exactly. And that's really what we're about. And that's really what healthcare and life science and biotech is about, because it's not a fad. It's not something that's gonna go over a period of time and maybe go out of uh
15:28Unidentified speaker (speaker_0): well that kind of viral, I guess. Different viral.
15:31Unidentified speaker (speaker_2): Yeah, yeah. I don't know of anybody who says, Is I want that medication that was twenty 20 years ago that's half price and that procedure that you know yeah. Yeah,
15:39Unidentified speaker (UNKNOWN): exactly.
15:40Unidentified speaker (speaker_2): I want the latest.
15:41Unidentified speaker (speaker_0): Yeah, absolutely. Well, thank you so much for joining us. Thank you for coming all this way to have a conversation with someone that is probably down the block from you. But I appreciate it. I appreciate the opportunity to chat with you and catch up and and also to share your own entrepreneurial journey with our either current entrepreneurs or wannabe want to be entrepreneurs. It's not easy, but if you hang in there.
16:01Unidentified speaker (speaker_2): Absolutely. And I I appreciate you and all that you've done, both for the ecosystem here, but for Oklahoma. Yeah. I know you've been involved with the nonprofits, with university, with
16:10Unidentified speaker (UNKNOWN): your
16:11Unidentified speaker (speaker_2): own endeavors there. And as we all know, those are things you have to work uphill.
16:16Unidentified speaker (speaker_0): Yeah.
16:16Unidentified speaker (UNKNOWN): But you
16:17Unidentified speaker (speaker_0): have to get back.
16:17Unidentified speaker (speaker_2): That's right. Exactly. And your mentoring and all of that. So thank you for all the work that you've been doing to help grow grab these. the
16:23Unidentified speaker (UNKNOWN): I'm happy to
16:24Unidentified speaker (speaker_0): do it. It takes a village. I had a village, so I got to be gotta the village. for somebody else at some point too. So you were my village at some
16:30Unidentified speaker (UNKNOWN): point,
16:30Unidentified speaker (speaker_0): so and vice versa. So
16:32Unidentified speaker (speaker_2): absolutely.
16:33Unidentified speaker (speaker_0): Well great. Well, as always, we'll have information about Craig Molecular, as well as the book he mentioned on our podcast and our show notes. Be sure to check them out and tune in next week for Bio from the Bayou.
16:44Unidentified speaker (speaker_1): Thanks for joining us for Bio from the Bayou. And we hope you'll join us again.
16:48Unidentified speaker (UNKNOWN): To
16:48Unidentified speaker (speaker_0): never miss the latest updates in biotech, hit the subscribe. button now.
16:52Unidentified speaker (speaker_1): We'll catch you on our next episode of Bio from the Bayou.
17:02Unidentified speaker (speaker_0): This podcast was edited by Resonate Recordings.